{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:06:01Z","timestamp":1789383961154,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Conafay Group"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40487-026-00453-8","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T20:51:52Z","timestamp":1782075112000},"page":"1011-1024","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Actionability Analysis of Comprehensive Genomic Profiling Versus Single\/Small-Gene Panels"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9934-3860","authenticated-orcid":false,"given":"Paul","family":"Spin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bela","family":"Bapat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Moretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dumanois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne M.","family":"Gilligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Shokoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Borgundvaag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Bifulco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,21]]},"reference":[{"key":"453_CR1","first-page":"1","volume":"8","author":"DM Thomas","year":"2021","unstructured":"Thomas DM, Hackett JM, Plestina S. Unlocking Access to Broad Molecular Profiling: Benefits, Barriers, and Policy Solutions. Public Health Genom. 2021;8:1\u201310.","journal-title":"Public Health Genom"},{"key":"453_CR2","unstructured":"OncoKB. Actionable Genes [updated 2024. Available from: https:\/\/www.oncokb.org\/actionable-genes#sections=Tx."},{"issue":"5","key":"453_CR3","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1377\/hlthaff.2017.1624","volume":"37","author":"GS Ginsburg","year":"2018","unstructured":"Ginsburg GS, Phillips KA. Precision medicine: from science to value. Health Aff (Millwood). 2018;37(5):694\u2013701.","journal-title":"Health Aff (Millwood)"},{"key":"453_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1200\/EDBK_174176","volume":"37","author":"L Schwartzberg","year":"2017","unstructured":"Schwartzberg L, Kim ES, Liu D, Schrag D. Precision oncology: who, how, what, when, and when not? Am Soc Clin Oncol Educ Book. 2017;37:160\u20139.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"453_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2013.03.002","volume":"153","author":"LA Garraway","year":"2013","unstructured":"Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013;153(1):17\u201337.","journal-title":"Cell"},{"issue":"11","key":"453_CR6","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1158\/2159-8290.CD-21-0126","volume":"11","author":"P Horak","year":"2021","unstructured":"Horak P, Heining C, Kreutzfeldt S, Hutter B, Mock A, Hullein J, et\u00a0al. Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov. 2021;11(11):2780\u201395.","journal-title":"Cancer Discov"},{"issue":"8","key":"453_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s41576-021-00338-8","volume":"22","author":"D Chakravarty","year":"2021","unstructured":"Chakravarty D, Solit DB. Clinical cancer genomic profiling. Nat Rev Genet. 2021;22(8):483\u2013501.","journal-title":"Nat Rev Genet"},{"key":"453_CR8","first-page":"8","volume":"2","author":"SF Basharat","year":"2022","unstructured":"Basharat SF, Horton J. CADTH horizon scan: an overview of comprehensive genomic profiling technologies to inform cancer care. Can J Health Technol. 2022;2:8.","journal-title":"Can J Health Technol."},{"issue":"6","key":"453_CR9","doi-asserted-by":"publisher","first-page":"e569","DOI":"10.3747\/co.27.5995","volume":"27","author":"KM Johnston","year":"2020","unstructured":"Johnston KM, Sheffield BS, Yip S, Lakzadeh P, Qian C, Nam J. Comprehensive genomic profiling for non-small-cell lung cancer: health and budget impact. Curr Oncol. 2020;27(6):e569\u201377.","journal-title":"Curr Oncol"},{"issue":"6","key":"453_CR10","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1634\/theoncologist.2016-0030","volume":"21","author":"JH Suh","year":"2016","unstructured":"Suh JH, Johnson A, Albacker L, Wang K, Chmielecki J, Frampton G, et\u00a0al. Comprehensive genomic profiling facilitates implementation of the national comprehensive cancer network guidelines for lung cancer biomarker testing and identifies patients who may benefit from enrollment in mechanism-driven clinical trials. Oncologist. 2016;21(6):684\u201391.","journal-title":"Oncologist"},{"issue":"5","key":"453_CR11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41576-021-00431-y","volume":"23","author":"I Cortes-Ciriano","year":"2022","unstructured":"Cortes-Ciriano I, Gulhan DC, Lee JJ, Melloni GEM, Park PJ. Computational analysis of cancer genome sequencing data. Nat Rev Genet. 2022;23(5):298\u2013314.","journal-title":"Nat Rev Genet"},{"key":"453_CR12","unstructured":"Centers for Medicare & Medicaid Services. Billing and Coding: MolDX: Targeted and Comprehensive Genomic Profile Next Generation Sequencing Testing in Cancer [updated 2024. Available from: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/article.aspx?articleId=55197#:~:text=Comprehensive%20Genomic%20Profile%20."},{"key":"453_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1101\/cshperspect.a034579","volume":"9","author":"EY Zhao","year":"2019","unstructured":"Zhao EY, Jones M, Jones SJM. Whole-genome sequencing in cancer. Cold Spring Harb Perspect Med. 2019;9:3.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"453_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","volume":"15","author":"M Nikanjam","year":"2022","unstructured":"Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15(1):131.","journal-title":"J Hematol Oncol"},{"key":"453_CR15","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061\u20138.","DOI":"10.1038\/nature07385"},{"issue":"2","key":"453_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/annonc\/mdx786","volume":"29","author":"V Prasad","year":"2018","unstructured":"Prasad V. Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of Foundation Medicine (F1CDx) before paying for it. Ann Oncol. 2018;29(2):298\u2013300.","journal-title":"Ann Oncol"},{"issue":"6367","key":"453_CR17","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1126\/science.aao6708","volume":"358","author":"R Eisenberg","year":"2017","unstructured":"Eisenberg R, Varmus H. Insurance for broad genomic tests in oncology. Science. 2017;358(6367):1133\u20134.","journal-title":"Science"},{"issue":"1","key":"453_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1053\/j.seminoncol.2016.01.005","volume":"43","author":"T Fojo","year":"2016","unstructured":"Fojo T. Precision oncology: a strategy we were not ready to deploy. Semin Oncol. 2016;43(1):9\u201312.","journal-title":"Semin Oncol"},{"key":"453_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/jpm8030030","volume":"8","author":"M Morash","year":"2018","unstructured":"Morash M, Mitchell H, Beltran H, Elemento O, Pathak J. The role of next-generation sequencing in precision medicine: a review of outcomes in oncology. J Pers Med. 2018;8:3.","journal-title":"J Pers Med."},{"issue":"9","key":"453_CR20","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.jval.2018.06.011","volume":"21","author":"JR Trosman","year":"2018","unstructured":"Trosman JR, Weldon CB, Gradishar WJ, Benson AB 3rd, Cristofanilli M, Kurian AW, et\u00a0al. From the past to the present: insurer coverage frameworks for next-generation tumor sequencing. Value Health. 2018;21(9):1062\u20138.","journal-title":"Value Health"},{"key":"453_CR21","first-page":"3","volume":"11","author":"D Horgan","year":"2023","unstructured":"Horgan D, Hamdi Y, Lal JA, Nyawira T, Meyer S, Kondji D, et\u00a0al. Framework for adoption of next-generation sequencing (NGS) globally in the oncology area. Healthcare (Basel). 2023;11:3.","journal-title":"Healthcare (Basel)."},{"issue":"2","key":"453_CR22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.6004\/jnccn.2017.0022","volume":"15","author":"JR Trosman","year":"2017","unstructured":"Trosman JR, Weldon CB, Douglas MP, Kurian AW, Kelley RK, Deverka PA, et\u00a0al. Payer coverage for hereditary cancer panels: barriers, opportunities, and implications for the precision medicine initiative. J Natl Compr Canc Netw. 2017;15(2):219\u201328.","journal-title":"J Natl Compr Canc Netw"},{"key":"453_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41\u201355.","journal-title":"Biometrika"},{"key":"453_CR24","unstructured":"Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et\u00a0al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol. 2017;2017."},{"key":"453_CR25","unstructured":"OncoKB. OncoKB Therapeutic Levels of Evidence [updated 2024. Available from: https:\/\/www.oncokb.org\/content\/files\/levelOfEvidence\/V2\/LevelsOfEvidence.pdf."},{"key":"453_CR26","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00075","volume":"8","author":"J Wallenta Law","year":"2024","unstructured":"Wallenta Law J, Bapat B, Sweetnam C, Mohammed H, McBratney A, Izano MA, et\u00a0al. Real-world impact of comprehensive genomic profiling on biomarker detection, receipt of therapy, and clinical outcomes in advanced non-small cell lung cancer. JCO Precis Oncol. 2024;8:e2400075.","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"453_CR27","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et\u00a0al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382.","journal-title":"Am J Epidemiol"},{"issue":"3","key":"453_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1\u201367.","journal-title":"J Stat Softw"},{"issue":"4","key":"453_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","volume":"30","author":"IR White","year":"2011","unstructured":"White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30(4):377\u201399.","journal-title":"Stat Med"},{"issue":"28","key":"453_CR30","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661\u201379.","journal-title":"Stat Med"},{"key":"453_CR31","volume":"31","author":"K Perdrizet","year":"2022","unstructured":"Perdrizet K, Stockley TL, Law JH, Smith A, Zhang T, Fernandes R, et\u00a0al. Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system. Cancer Treat Res Commun. 2022;31:100534.","journal-title":"Cancer Treat Res Commun"},{"issue":"2","key":"453_CR32","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40487-024-00270-x","volume":"12","author":"MK Nesline","year":"2024","unstructured":"Nesline MK, Subbiah V, Previs RA, Strickland KC, Ko H, DePietro P, et\u00a0al. The impact of prior single-gene testing on comprehensive genomic profiling results for patients with non-small cell lung cancer. Oncol Ther. 2024;12(2):329\u201343.","journal-title":"Oncol Ther"},{"key":"453_CR33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e21114","author":"B Bapat","year":"2022","unstructured":"Bapat B, Sweetnam C, McBratney A, Izano MA, Schroeder B, Walters S, et\u00a0al. Actionability of comprehensive genomic profiling (CGP) compared to single-gene and small panels in patients with advanced\/metastatic non-small cell lung cancer (aNSCLC): A real-world study. J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.e21114.","journal-title":"J Clin Oncol"},{"key":"453_CR34","unstructured":"American Cancer Society Cancer Action Network. Payer Coverage Policies of Tumor Biomarker and Pharmacogenomic Testing. 2023."},{"issue":"1","key":"453_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/13696998.2022.2154479","volume":"26","author":"LM Hess","year":"2023","unstructured":"Hess LM, Michael D, Krein PM, Marquart T, Sireci AN. Costs of biomarker testing among patients with metastatic lung or thyroid cancer in the USA: a real-world commercial claims database study. J Med Econ. 2023;26(1):43\u201350.","journal-title":"J Med Econ"},{"issue":"3","key":"453_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41391-021-00469-3","volume":"25","author":"N Weise","year":"2022","unstructured":"Weise N, Shaya J, Javier-Desloges J, Cheng HH, Madlensky L, McKay RR. Disparities in germline testing among racial minorities with prostate cancer. Prostate Cancer Prostatic Dis. 2022;25(3):403\u201310.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"453_CR37","doi-asserted-by":"publisher","first-page":"e784","DOI":"10.1200\/OP.22.00634","volume":"19","author":"LG Briggs","year":"2023","unstructured":"Briggs LG, Steele GL, Qian ZJ, Subbana S, Alkhatib KY, Labban M, et\u00a0al. Racial differences in germline genetic testing for prostate cancer: a systematic review. JCO Oncol Pract. 2023;19(5):e784\u201393.","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"453_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11606-020-06064-x","volume":"36","author":"E Chapman-Davis","year":"2021","unstructured":"Chapman-Davis E, Zhou ZN, Fields JC, Frey MK, Jordan B, Sapra KJ, et\u00a0al. Racial and ethnic disparities in genetic testing at a hereditary breast and ovarian cancer center. J Gen Intern Med. 2021;36(1):35\u201342.","journal-title":"J Gen Intern Med"},{"issue":"2","key":"453_CR39","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1001\/jamaoncol.2018.4616","volume":"5","author":"DL Steward","year":"2019","unstructured":"Steward DL, Carty SE, Sippel RS, Yang SP, Sosa JA, Sipos JA, et\u00a0al. Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study. JAMA Oncol. 2019;5(2):204\u201312.","journal-title":"JAMA Oncol"},{"key":"453_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051156","author":"AP Singh","year":"2020","unstructured":"Singh AP, Shum E, Rajdev L, Cheng H, Goel S, Perez-Soler R, et\u00a0al. Impact and diagnostic gaps of comprehensive genomic profiling in real-world clinical practice. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12051156.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"453_CR41","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/s41591-025-03613-x","volume":"31","author":"O Tr\u00e9dan","year":"2025","unstructured":"Tr\u00e9dan O, Pouessel D, Penel N, Chabaud S, Gomez-Roca C, Delord JP, et\u00a0al. Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial. Nat Med. 2025;31(5):1502\u20138.","journal-title":"Nat Med"},{"issue":"3","key":"453_CR42","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/picr.picr_62_21","volume":"12","author":"D Chodankar","year":"2021","unstructured":"Chodankar D. Introduction to real-world evidence studies. Perspect Clin Res. 2021;12(3):171\u20134.","journal-title":"Perspect Clin Res"},{"issue":"3","key":"453_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/dom.14021","volume":"22","author":"JD Seeger","year":"2020","unstructured":"Seeger JD, Nunes A, Loughlin AM. Using RWE research to extend clinical trials in diabetes: an example with implications for the future. Diabetes Obes Metab. 2020;22(3):35\u201344.","journal-title":"Diabetes Obes Metab"},{"issue":"21","key":"453_CR44","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1200\/JCO.24.00662","volume":"42","author":"N Tung","year":"2024","unstructured":"Tung N, Ricker C, Messersmith H, Balma\u00f1a J, Domchek S, Stoffel EM, et\u00a0al. Selection of germline genetic testing panels in patients with cancer: ASCO guideline. J Clin Oncol. 2024;42(21):2599\u2013615.","journal-title":"J Clin Oncol"},{"issue":"1","key":"453_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00392-016-1025-6","volume":"106","author":"MR Cowie","year":"2017","unstructured":"Cowie MR, Blomster JI, Curtis LH, Duclaux S, Ford I, Fritz F, et\u00a0al. Electronic health records to facilitate clinical research. Clin Res Cardiol. 2017;106(1):1\u20139.","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"453_CR46","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.semradonc.2019.05.010","volume":"29","author":"E Kim","year":"2019","unstructured":"Kim E, Rubinstein SM, Nead KT, Wojcieszynski AP, Gabriel PE, Warner JL. The evolving use of electronic health records (EHR) for research. Semin Radiat Oncol. 2019;29(4):354\u201361.","journal-title":"Semin Radiat Oncol"},{"issue":"7","key":"453_CR47","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.18632\/oncotarget.2925","volume":"6","author":"SY Ha","year":"2015","unstructured":"Ha SY, Choi SJ, Cho JH, Choi HJ, Lee J, Jung K, et\u00a0al. Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR. Oncotarget. 2015;6(7):5465\u201374.","journal-title":"Oncotarget"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00453-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00453-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00453-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:32:21Z","timestamp":1789381941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00453-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,21]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["453"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00453-8","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,21]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"John Fox is a full-time employee at Illumina, Inc., manufacturer of sequencers for both large and small panels discussed in this manuscript. Bela Bapat is a full-time employee and stock owner at Illumina, Inc., and declares that Illumina, Inc. has no financial interest in or financial conflict with the subject matter discussed in the manuscript. Carlo Bifulco reports stock ownership and serving on scientific advisory board of PrimeVax, BioAI, and Pictor Labs, serving on scientific advisory board of Lunaphore, consulting or advisory relationships (compensated) at Sanofi, Agilent, Roche, Incendia, Bristol Myers Squibb (BMS), and receiving institutional research support from Illumina, Inc. These disclosures are unrelated to the preparation of the current manuscript, with the exception of the institutional research support from Illumina Inc., and no entity had any influence over the research content or interpretation. Robert Dumanois is an employee and stock owner of Thermo Fisher Scientific and declares that Thermo Fisher Scientific does not have any financial interest in or financial conflict with the subject matter discussed in the manuscript. Adrienne M. Gilligan is an employee and stock owner of Eli Lilly and Company and declares that Eli Lilly and Company does not have any financial interest in or financial conflict with the subject matter discussed in the manuscript. Paul Spin, Mostafa Shokoohi, and Emily Borgundvaag are employees of EVERSANA, which consults for biomedical and pharmaceutical companies, and declare that EVERSANA has no financial interest in or financial conflict with the subject matter discussed in the manuscript. Chad Moretz and David Bartlett declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data used in the study have been certified as statistically de-identified by an independent third-party such that, this study does not require review and approval by ethics committees. Informed consent and consent for publication were not applicable as this was a retrospective study without active patient recruitment, and all retrieved clinical data were deidentified. The study was conducted in accordance with the Helsinki Declaration of 1964, and its later amendments.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}